ESC 365 - Why could patients with heart failure and T2DM benefit from SGLT2 inhibition?

HFA Premium Access

Why could patients with heart failure and T2DM benefit from SGLT2 inhibition?

Session: Heart Failure, diabetes & SGLT2 inhibition: time to change practice?

Topic: Pathophysiology and Mechanisms

Speaker: Professor S. Verma (Toronto, CA)

Organised by PACE-CME, Physicians' Academy for Cardiovascular Education, supported with an educational grant from Boehringer Ingelheim

Event: Heart Failure 2019

Congress Presentation

Add to my library

About the speaker

Professor Subodh Verma

St. Michael's Hospital, Toronto (Canada)

31 presentations

3 followers

4 more presentations in this session

The essentials for diabetes and heart failure.

Speaker: Professor M. Cowie (Cambridge, GB)

Real world practices and outcomes in the management of heart failure patients with T2DM.

Speaker: Professor C. Lam (Singapore, SG)

The future of SGLT2 inhibition in heart failure: managing patients without T2DM?

Speaker: Professor A. Voors (Groningen, NL)

Panel discussion - Heart Failure, diabetes & SGLT2 inhibition: time to change practice?

Speaker: Professor M. Cowie (Cambridge, GB)

Access the full session

Heart Failure, diabetes & SGLT2 inhibition: time to change practice?

Speakers: Professor S. Verma, Professor M. Cowie, Professor C. Lam, Professor A. Voors, Professor M. Cowie

About the event

Heart Failure 2019

25 May - 28 May 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources